Hospital acquired Infection Diagnostics Market Report 2025 (Global Edition)

Global Hospital acquired Infection Diagnostics Market Report 2025 Market Size Split by Product (Instrument, Reagents, Consumables), by Test Type (Molecular Diagnostics, Immunoassay, Others), by Applic...

Hospital acquired Infection Diagnostics Market Report Description

We have various report editions of Hospital acquired Infection Diagnostics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Hospital acquired Infection Diagnostics Market Insights Video

Competitive Landscape of the Hospital-Acquired Infection Diagnostic Market

There is fierce competition amongst different companies in the hospital-acquired infection (HAI) diagnostic sector, from well-established global firms to creative startups. Ongoing technological developments, tactical partnerships, and an emphasis on product creation to satisfy the rising need for efficient HAI diagnostics all influence the competitive environment.

February 2024: The world leader in artificial intelligence (AI)-driven pathology technology, PathAI, and Roche announced their partnership. To develop AI-enabled digital pathology algorithms in the companion diagnostics arena, PathAI will exclusively collaborate with Roche Tissue Diagnostics (RTD) under the parameters of this agreement. As the only outside algorithm development business for AI-powered companion diagnostics, RTD will collaborate solely with PathAI for a predetermined period, with the option to continue developing its own companion diagnostics algorithms. PathAI will continue to be free to create algorithms for purposes other than companion diagnostics. Source: https://diagnostics.roche.com/global/en/news-listing/2024/roche-enters-into-collaboration-agreement-with-pathai-to-expand-digital-pathology-capabilities.html.

 

Top Companies Market Share in Hospital acquired Infection Diagnostics Industry: (In no particular order of Rank)

• HOLOGIC
• INC.
• MERCK KGaA
• BECTON DICKINSON AND COMPANY
• BAYER SCHERING PHARMA LLC
• STERIS PLC
• JOHNSON & JOHNSON
• ABBOTT LABORATORIES
• ECOLAB
• DANAHER CORPORATION
• PFIZER INC.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Hospital-Acquired Infection Diagnostic Market

Which Region Dominates the Hospital-Acquired Infection Diagnostic Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. North America, in particular the US and Canada, has highly developed healthcare systems completed with cutting-edge hospitals and diagnostic centers. The use of cutting-edge diagnostic technology is facilitated by this infrastructure. Moreover, HAIs continue to be a major concern in North America even with modern healthcare facilities. The need for efficient diagnostic tools to quickly identify and treat these illnesses is fueled by their high frequency.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Hospital-Acquired Infection Diagnostic market. The Asia-Pacific (APAC) hospital-acquired infection (HAI) diagnostic market is expanding quickly as a result of several factors, such as rising healthcare expenditures, an increase in the frequency of HAIs, and the use of cutting-edge diagnostic technologies. The area offers substantial prospects for market growth, propelled by advancements in both healthcare and the economy.

The current report Scope analyzes Hospital acquired Infection Diagnostics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Hospital acquired Infection Diagnostics

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size was estimated at USD 29845.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 11938.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.1% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Hospital-Acquired Infection Diagnostic market with a market size of USD 9419.15 million in 2024 and is projected to grow at a CAGR of 0.9% during the forecast period. The demand is amplified by the nation's developed healthcare infrastructure.
• The Canada Hospital-Acquired Infection Diagnostic market had a market share of USD 1432.57 million in 2024 and is projected to grow at a CAGR of 1.9% during the forecast period. Canada's growing investment.
• The Mexico Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.6% during the forecast period, with a market size of USD 1086.37 million in 2024.

Europe Hospital acquired Infection Diagnostics

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size was estimated at USD 29845.2 Million out of which Europe held the market more than 30% of the global revenue with a market size of USD 8953.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.4% from 2024 to 2031.

• The United Kingdom Hospital-Acquired Infection Diagnostic market had a market share of USD 1504.20 million in 2024 and is projected to grow at a CAGR of 2.2% during the forecast period. In the UK, Hospital-Acquired Infection Diagnostic sales witness an upswing due to the growing product launch.
• The France Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 0.6% during the forecast period, with a market size of USD 823.73 million in 2024.
• According to Cognitive Market Research, the German Hospital-Acquired Infection Diagnostic market size was valued at USD 1772.80 million in 2024 and is projected to grow at a CAGR of 1.6% during the forecast period. In Germany, Hospital-Acquired Infection Diagnostic sales surged due to the increasing investment.
• The Italy Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 0.8% during the forecast period, with a market size of USD 770.01 million in 2024.
• The Russia Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 0.4% during the forecast period, with a market size of USD 1387.80 million in 2024.
• The Spain Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 0.5% during the forecast period with a market size of USD 734.19 million in 2024
• The Luxembourg Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.5% during the forecast period, with a market size of USD 277.56 million in 2024.
• The Portugal Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.2% during the forecast period, with a market size of USD 188.02 million in 2024.
• The Greece Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.7% during the forecast period, with a market size of USD 107.44 million in 2024.
• Rest of Europe's Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 0.1% during the forecast period, with a market size of USD 1387.80 million in 2024.

Asia Pacific Hospital acquired Infection Diagnostics

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size was estimated at USD 29845.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 6864.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.

• According to Cognitive Market Research, the China Hospital-Acquired Infection Diagnostic market size was valued at USD 3088.98 million in 2024 and is projected to grow at a CAGR of 4.4% during the forecast period. Hospital-Acquired Infection Diagnostic sales surged in China due to increasing product launches.
• The Japan Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 3.4% during the forecast period, with a market size of USD 947.29 million in 2024.
• The India Hospital-Acquired Infection Diagnostic market had a market share of USD 823.73 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. India's growing healthcare expenditure.
• The South Korea Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 686.44 million in 2024.
• The Australia Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 356.95 million in 2024.
• The South East Asia Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 473.64 million in 2024.
• The Rest of the Asia Pacific Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 487.37 million in 2024.

South America Hospital acquired Infection Diagnostics

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size was estimated at USD 29845.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 1492.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.3% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Hospital-Acquired Infection Diagnostic market size was valued at USD 638.69 million in 2024 and is projected to grow at a CAGR of 2.9% during the forecast period. Hospital-Acquired Infection Diagnostic sales flourish in Brazil due to rising technological advancement.
• Argentina Hospital-Acquired Infection Diagnostic market had a market share of USD 250.70 million in 2024 and is projected to grow at a CAGR of 3.2% during the forecast period. The growing investment drives the market growth in the nation.
• Colombia Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 2.1% during the forecast period with a market size of USD 132.81 million in 2024.
• Peru Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD 122.37 million in 2024.
• Chile Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 107.44 million in 2024.
• The Rest of Latin America Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.4% during the forecast period, with a market size of USD 240.25 million in 2024.

Middle East Hospital acquired Infection Diagnostics

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size was estimated at USD 29845.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 596.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.6% from 2024 to 2031.

• The GCC Countries Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 3.4% during the forecast period with a market size of USD 255.47 million in 2024. Hospital-Acquired Infection Diagnostic sales flourish due to the growing healthcare infrastructure.
• The Egypt Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 2.9% during the forecast period, with a market size of USD 62.67 million in 2024.
• The South Africa Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 94.31 million in 2024. Hospital-Acquired Infection Diagnostic sales flourish in South Africa due to the rising investment.
• The Turkey Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 2.1% during the forecast period, with a market size of USD 51.33 million in 2024.
• The Nigeria Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.7% during the forecast period, with a market size of USD 62.67 million in 2024.
• The Rest of MEA Hospital-Acquired Infection Diagnostic market is projected to witness growth at a CAGR of 1.6% during the forecast period, with a market size of USD 70.43 million in 2024.

Hospital acquired Infection Diagnostics Market Analysis

Hospital-Acquired Infection Diagnostic Market Product Segment Analysis

According to Cognitive Market Research, Reagents and Consumables stand out as the dominating category due to the increased prevalence of HAIs. Antibiotic therapy is the most common method of treating nosocomial infections. Medical exams help pinpoint the exact microbes responsible for a patient's illness. The first course of treatment may involve the use of common broad-spectrum antibiotics such as erythromycin, penicillin, cephalosporins, or tetracyclines. However, repeated use of antibiotics for prolonged periods by patients with chronic illnesses might cause some bacteria to become increasingly resistant to these widely used antibiotic medicines, reducing their efficacy.

Instrument emerges as the fastest-growing category in the Hospital-Acquired Infection Diagnostic market. The accuracy, speed, and dependability of HAI detection are being improved by ongoing innovation in diagnostic technologies, such as automated platforms, next-generation sequencing (NGS), and molecular diagnostics. The need for advanced diagnostic tools is being driven by these developments.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Hospital acquired Infection Diagnostics Industry. Request a Free Sample PDF!

Hospital-Acquired Infection Diagnostic Market Test Type Segment Analysis

According to Cognitive Market Research, the dominating category is Immunoassay. The segment expansion is attributed to technological advancements. Higher sensitivity and specificity are provided by new immunoassay technologies, increasing the precision of HAI detection. The way is being led by innovations like enzyme-linked immunosorbent tests (ELISA) and chemiluminescence immunoassays (CLIA). Moreover, the need for quick and precise diagnostic testing is fueled by the rising prevalence of HAIs in healthcare environments. Because of their reliability and speedy turnaround times, immunoassays are widely used, which boosts their revenue development.

The fastest-growing category in the Hospital-Acquired Infection Diagnostic market is Molecular Diagnostics. The hospital-acquired infection (HAI) diagnostic market is heavily dependent on molecular diagnostics because of its high sensitivity, specificity, and quick turnaround times. Technological developments, the rising incidence of HAIs, and the demand for quick and precise diagnostic techniques are all contributing to this segment's significant revenue growth.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Hospital acquired Infection Diagnostics Application Segment Analysis

Application Segment Analysis

According to Cognitive Market Research, the dominating category is Disease Testing. The need for sophisticated diagnostic techniques is being driven by the rising incidence of HAIs throughout the world. Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant Enterococci (VRE), and pseudomonas aeruginosa are common bacteria that cause health-associated infections (HAIs). Furthermore, the accuracy and speed of HAI detection are improved by advancements in diagnostic technologies, such as molecular diagnostics, immunoassays, and next-generation sequencing (NGS). Revenue growth is mostly attributable to these developments.

The fastest-growing category in the Hospital-Acquired Infection Diagnostic market is Drug-Resistance Testing. Due to the urgency of identifying resistant strains and directing appropriate antimicrobial therapy, there is an increasing need for precise and speedy drug-resistance testing.

• Disease Testing
• Drug-Resistance Testing

Hospital acquired Infection Diagnostics Infection Type Segment Analysis

Infection Type Segment Analysis

According to Cognitive Market Research, the dominating category is Hospital Acquired Pneumonia. One of the most prevalent HAIs is HAP, which mostly affects patients receiving mechanical ventilation and those in critical care units (ICUs). There is a strong need for trustworthy diagnostic tools due to the high prevalence. The speed and accuracy of HAP diagnosis are improved by advancements in diagnostic technology, including molecular diagnostics, fast antigen testing, and biomarker assays. These developments greatly aid in the expansion of the market.

The fastest-growing category in the Hospital-Acquired Infection Diagnostic market is Urinary Tract Infections (UTI). Hospitalized individuals frequently get urinary tract infections (UTIs), particularly those undergoing invasive procedures or urine catheterization. The need for effective diagnostic treatments is driven by the recurrent occurrence.

• Hospital Acquired Pneumonia
• Bloodstream Infections
• Surgical Site Infections
• Gastrointestinal Infections
• Urinary Tract Infections (UTI)
• Others

Hospital acquired Infection Diagnostics End User Segment Analysis

End User Segment Analysis

According to Cognitive Market Research, the dominating category is Hospital. A greater understanding of hospital-acquired infections is being facilitated by hospitals. Hospitals are placing more focus on personal cleanliness as a result of the recent spike in COVID-19 cases. Revenue growth in this market is being driven by hospitals' improved use of HAI diagnostics, such as blood culture tests, PCR testing, and immunoassays, for surgery site infections.

The fastest-growing category in the Hospital-Acquired Infection Diagnostic market is Standalone Laboratories. Modern diagnostic tools, including automated culture systems, point-of-care testing (POCT) devices, immunoassays, and molecular diagnostics (PCR, NGS) are available in standalone labs. Antimicrobial resistance indicators and infections can be detected quickly and precisely thanks to these methods. They provide a broad range of testing capabilities, including molecular tests for quick detection, culture-based approaches for pathogen identification and susceptibility testing, and biomarker assays for determining the severity of infections and informing treatment choices.

• Hospital
• Standalone Laboratories
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion